Tebentafusp-tebn (Kimmtrak, Immunocore) — the only FDA-approved treatment for this indication — is the first T-cell receptor therapeutic to receive regulatory approval.
Regulatory
FDA Approves Tebentafusp-tebn for Unresectable or Metastatic Uveal Melanoma
The FDA has approved tebentafusp-tebn (Kimmtrak) for the treatment of HLA-A*02:01–positive adult patients with unresectable or metastatic uveal melanoma.
FDA grants fast track designation to BNT111 for advanced melanoma
BNT111 (BioNTech) — an investigational cancer immunotherapy — uses a fixed combination of mRNA-encoded, tumor-associated antigens designed to activate a precise and strong immune response against cancer.
FDA Approves Adjuvant Pembrolizumab for Stage IIB or IIC Melanoma Following CR
The FDA has approved pembrolizumab (Keytruda) for the adjuvant treatment of adult and pediatric patients with stage IIB or IIC melanoma following complete resection (CR).